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Genetics Advocacy: Opportunity and Obligation
Advocacy is deﬁned as supporting, pleading, or giving voice
to the cause of another. Genetics advocacy, through commu-
nication with elected ofﬁcials and policy makers, is critical to
the passage of legislation and the implementation of policies
that support basic research, enhance translation of research,
and improve genetic services. The future of genetics research
as well as the translation of genetics ﬁndings into clinical care
rests in large part on the successful advocacy by its propo-
nents—both scientists and consumers. It is no exaggeration to
state that successfully educating policy makers, the public, pro-
viders, insurers, and others is one key to actualizing the po-
tential beneﬁts of genetics for humanity and to enabling con-
tinued research. Scientists who understand genetics and its
potential are well positioned with both information and cred-
ibility to serve as advocates.
Reasons
Congress, state legislatures, and policy makers at all levels have
numerous important competing issues and priorities. Whereas
scientists deal with subjects in depth and (sometimes excru-
ciating) detail, policy makers must approach a multitude of
topics from a perspective of breadth rather than depth. Elected
ofﬁcials are expected to have working knowledge of a wide
variety of complex and essential issues, including everything
from billion-dollar budgeting and tax systems to defense and
foreign policy, travel and communications infrastructure, and
medical and other public support programs.
To elevate and highlight science, support of research- and
genetics-related issues on the agendas of policy makers is the
responsibility of our community. Geneticists have the knowl-
edge and understanding to communicate to decision makers
the importance of human genetics research to human health.
Issues and Partners
The American Society of Human Genetics (ASHG) has been
active in tracking, promoting, and educating legislators and
regulators about several current issues that are of critical im-
portance to the genetics community. ASHG partners with other
organizations through several national coalitions to enhance
its effectiveness, visibility, and clout.
ASHG has been working with the Coalition for Genetic
Fairness, including a primary partnership with the Genetic Al-
liance, to succeed in the passage of federal genetic-nondiscrim-
ination legislation. In the 108th Congress, the Senate passed
a bill of this type 98–0, the second time such legislation has
been unanimously passed by the Senate. The most recent ge-
netics-related House of Representatives bill (HR 1227) has had
strong bipartisan support, with 1150 cosponsors. Current in-
formation regarding the legislation is available at the ASHG
Web site (http://www.ashg.org/) and the Coalition for Genetic
Fairness Web site (http://www.geneticfairness.org/). Additional
support will be needed, and ASHG members may be called on
to contact their elected representatives.
In collaboration with the Federation of American Societies
of Experimental Biology (FASEB), Research!America, and the
Association of American Medical Colleges (AAMC), the So-
ciety also works each year to enhance federal funding for re-
search, with a special (but not exclusive) focus on National
Institutes of Health (NIH) funding. The economic situation in
the United States is such that the genetics community must not
only continue but also greatly increase its activities to ensure
that research support is not further diminished. During the
next months, ASHG will also maintain vigilance and provide
appropriate input as the reauthorization of the NIH is con-
sidered by Congress.
Additional issues that will involve policy and possibly leg-
islative processes include but are not limited to stem cell re-
search; intellectual property issues, including patenting and
licensing; translation of genetic testing into practice; and the
regulation and quality control of genetic tests.
Methods
There are many ways, both proactive and reactive, to be a
genetics advocate. You may contact policy makers directly or
express your views through other public venues in writing or
by speaking. All forms of communication are important to
successful advocacy. The policy process can be slow and un-
predictable, so it is essential to be steadfast and always pre-
pared to capitalize on opportunities with regard to timing and
access.
First, one must understand the issues as well as the political
or policy (e.g., regulatory) process. This knowledge is essential
to recognize how one may impact the decision-making pro-
cess. An advocate must have a clear and concise message and
a clear request for action. Every approach should be accom-
panied by thanks for the listeners’ time and commitment to
public service. Possible actions include timely letters, e-mails,
or phone calls related to a speciﬁc issue, debate, meeting, or
vote. Visits to elected ofﬁcials or their staff can be made at
their legislative or home-district ofﬁces. Often, visits merely to
thank an individual or to provide background information on
speciﬁc issues, genetics, or scientiﬁc research may pave the way
for topic-speciﬁc visits or requests at a later date. The ASHG
Board of Directors is holding its spring meeting inWashington,
DC, and they will be visiting their own representatives and
other key legislators.
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Obligation
It is the obligation of citizens to become involved inmeaningful
issues, especially those for which they have unique and essen-
tial knowledge to educate and inform the elected and selected
leaders. If we do not participate, the issues important to our
lives will not be on the agenda. Constituents count! If we do
not speak, they cannot hear our voices. We must make our-
selves heard and be sure that our messages are clear and
concise.
The ofﬁcers and Board of Directors of ASHG will continue
to lead the organization in the development of messages, ac-
tivities, and speciﬁc calls to action for the membership on
urgent issues. If at any time there is a question about these
activities, you may contact Joann Boughman, ASHGExecutive
Vice President (jboughman@ashg.org).
JOANN A. BOUGHMAN
Executive Vice President
American Society of Human Genetics
